MedWatch

Symphogen receives new milestone payment

A deal between Symphogen and the German pharmaceutical player Merck KGaA worth billions will land more millions in the pockets of the Danish company, following completed clinical studies.

Foto: Symphogen

Symphogen will receive another milestone payment from its German partner, Merck, the Danish company reveals in a press release Wednesday.

The milestone payment is triggered as part of a licensing agreement worth DKK 3.7 billion (USD 646 million) between the two companies from September 2012 concerning further development of Symphogen’s cancer candidate, Sym004.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier